NCT04648930 - Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

November 3, 2022

Study Completion Date

November 3, 2022

Conditions

Allergic Rhinitis

Interventions

DRUG

Xolair

There was no treatment allocation. Patients administered Xolair by prescription that started before inclusion of the patient into the study were enrolled.

Trial Locations (16)

495-0002

Novartis Investigative Site, Inazawa

272-0143

Novartis Investigative Site, Ichikawa

270-1337

Novartis Investigative Site, Inzai

308-0031

Novartis Investigative Site, Chikusei

252-0231

Novartis Investigative Site, Sagamihara

252-0392

Novartis Investigative Site, Sagamihara

572-0082

Novartis Investigative Site, Neyagawa

102-0093

Novartis Investigative Site, Chiyoda City

813 0043

Novartis Investigative Site, Fukuoka

860-0814

Novartis Investigative Site, Kumamoto

604-0837

Novartis Investigative Site, Kyoto

604-8152

Novartis Investigative Site, Kyoto

850-0057

Novartis Investigative Site, Nagasaki

544-0033

Novartis Investigative Site, Osaka

545-8586

Novartis Investigative Site, Osaka

331-0802

Novartis Investigative Site, Saitama